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HUBUNGAN DI ANTARA KEPEKATAN ISONIAZID, RIFAMPICIN, 
PYRAZINAMIDE DALAM DARAH, DAN HASIL RAWATAN DALAM 
KALANGAN PESAKIT BATUK KERING (TUBERKULOSIS PULMONARI)  
 
ABSTRAK 
Sebuah kajian kohort prospektif dijalankan di Hospital Pulau Pinang bagi 
mengenal pasti penentu farmakokinetik INH (INH), rifampicin (RIF), and 
pyrazinamide (PZA), dan menilai kesan parameter farmakokinetik tersebut keatas 
dapat rawatan dalam kalangan pesakit tuberculosis pulmonari. Kepekatan INH, RIF, 
dan PZA plasma disukat menggunakan kaedah HPLC baharu yang dibangunkan dan 
pengesahannya adalah sebahagian daripada kajian ini. Median maksimum (Cmax) 
kepekatan INH, RIF, dan PZA darah adalah masing-masing 4.75, 6.85, dan 42.00 
mg/L. Median keluasan keluk masa-kepekatan dari sifar hingga 24 jam (AUC0-24h) 
bagi INH dan RIF masing-masing adalah 20.10, dan 33.22 mg × h/L. Log INH Cmax, 
dan log INH AUC0-24h adalah ketara lebih tinggi sebanyak 33% (P = 0.000), dan 25% 
(P = 0.000) bagi pesakit berbangsa India berbanding bangsa lain.  Log INH Cmax dan 
log INH AUC0-24h mengalami pengurangan sebanyak 20% (P = 0.042), dan sebanyak 
23% (P = 0.000) dalam kalangan pesakit yang ketagihan alkohol. Log RIF Cmax dan 
AUC0-24h bagi RIF adalah lebih tinggi sebanyak 14% (P = 0.018), 23% (P = 0.026) 
bagi pesakit diabetes. RIF AUC0-24h ketara lebih rendah bagi pesakit ketagih alkohol 
sebanyak 27.6%, P = 0.042. Log PZA Cmax menujukkan peningkatan ketara sebanyak 
5%, (P = 0.004), bagi pesakit berbangsa India.  Di penghujung fasa intensif, 84.7%  
pesakit yang pada awalnya positif ujian calitan memberikan keputusan calitan 
negatif. Pengubahan keputusan calitan kahak adalah signifikan dan memperoleh 
kesan positif daripada ukuran dasar berat badan pesakit (OR terselaras = 1.24; 95% 
xxi 
 
CI = 1.05 - 1.48, P = 0.011), kepekatan dasar protein total (OR terselaras = 1.20; 
95% CI = 1.02 - 1.41, P = 0.026), dan memperoleh kesan negatif akibat merokok 
(OR terselaras = 39.8%; 95% CI = 1.55 - 1023.2, P = 0.026). Kesan advers ubat 
(ADR) dikesan pada 29.2% pesakit. Insidens ADR ketara lebih tinggi pada pesakit 
bukan perokok (OR terselaras = 4.40; 95% CI = 1.39 - 13.94, P = 0.012), dan pada 
pesakit yang diberi INH C2h melebihi 3.4 mg/L (OR terselaras = 3.75; 95% CI = 1.18 
- 11.96, P = 0.025). Sebagai rumusan tidak terdapat satu hubungkait yang signifikan 
antara parameter farmakokinetik INH, RIF, dan PZA serta konversi calitan  atau 
dapatan rawatan terakhir untuk tuberkulosis pulmonari.  Walaubagaimanapun, 
insiden ADR untuk antituberkulosis adalah tinggi dalam kalangan pesakit yang 
mengambil INH C2h. Kajian yang lebih mendalam adalah diperlukan sebelum 
pemonitoran terapeutik drug (TDM) bagi rawatan tuberkulosis pulmonari dijalankan. 
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THE RELATIONSHIP BETWEEN THE BLOOD CONCENTRATION OF 
ISONIAZID, RIFAMPICIN, PYRAZINAMIDE AND THE TREATMENT 
OUTCOMES OF PULMONARY TUBERCULOSIS PATIENTS 
 
ABSTRACT 
A prospective cohort study was conducted in Hospital Pulau Pinang to find 
out the determinants of the pharmacokinetics of isoniazid (INH), rifampicin (RIF), 
and pyrazinamide (PZA), and to assess the effect of these pharmacokinetic 
parameters on the treatment outcomes of pulmonary tuberculosis patients. Plasma 
concentration of INH, RIF, and PZA was measured by new HPLC methods 
developed and validated as part of this study. The median of maximum plasma 
concentration (Cmax) of INH, RIF, and PZA was 4.75, 6.85, and 42.00 mg/L 
respectively. The median of the area under the time -concentration curve from zero 
to 24 hours (AUC0-24h) of INH and RIF was 20.1 and 33.2mg × h/ L respectively. 
The log INH Cmax, and log INH AUC0-24h were respectively significantly higher by 
33%, (P = 0.000), and 25% (P = 0.000) in Indian patients.  Log INH Cmax and log 
INH AUC0-24h were respectively reduced by 20% (P = 0.042), and by 23% (P = 
0.000) in alcoholic patients. Respectively, the log RIF Cmax and the AUC0-24h of RIF 
were higher by 14% (P = 0.018), 23% (P = 0.026) in diabetic patients. RIF AUC0-24h 
was significantly lower in alcoholic patients by 27.6% (P = 0.042).  Log PZA Cmax 
was significantly higher by 5% (P = 0.004), in Indian patients. At the end of 
intensive phase 84.7% of the initially smear positive patients were converted to 
smear negative status. The conversion of positive sputum smear was significant and 
positively affected by the baseline patients‟ body weight (adjusted OR = 1.24; 95% 
CI = 1.05 – 1.48, P = 0.011), the baseline total protein concentration (adjusted OR = 
xxiii 
 
1.20; 95% CI = 1.02 – 1.41, P = 0.026), and negatively affected by tobacco smoking 
(adjusted OR = 39.8%; 95% CI = 1.55 – 1023.2, P = 0.026). The final treatment 
outcomes were not significantly affected by any variable. Adverse drug reactions 
(ADRs) related to antituberculosis agents occurred in 29.2% of the patients. 
Incidence of ADRs was significantly higher in non-smoker patients (adjusted OR = 
4.40; 95% CI = 1.39 – 13.94, P = 0.012), and in patients who had INH C2h above 3.4 
mg/L (adjusted OR = 3.75; 95% CI = 1.18 – 11.96, P = 0.025). In conclusion, there 
was no significant relationship between the pharmacokinetic parameters of INH, 
RIF, and PZA and the sputum smear conversion or the final treatment outcomes of 
pulmonary tuberculosis. Nevertheless, the incidence of anti-TB ADRs was 
significantly higher in patients with higher INH C2h. Further studies are required 
before the therapeutic drug monitoring (TDM) can be utilized in the treatment of 
pulmonary tuberculosis.  
1 
 
CHAPTER 1 
INTRODUCTION 
 
1.1 Burden of tuberculosis 
Tuberculosis (TB) is a potentially fatal infectious disease caused by 
Mycobacterium tuberculosis. Although the disease mostly affects the lung causing 
pulmonary tuberculosis (PTB), any other organs in the body may also be infected 
which leads to extra-pulmonary tuberculosis (EPTB) (WHO, 2015). Tuberculosis is 
an ancient disease; the earliest evidence of its existence is dated back to 8000 BC 
(Herzog, 1998). Nowadays, TB is still one of the most important infectious diseases 
causing death in the world. In 2014 alone, the World Health Organization estimated 
that the incidence of TB was 9.6 million cases which is equivalent to 133 cases per 
100,000 individuals worldwide. More than half (58%) and about 28% of the 
estimated cases are residents in Asia and Africa, respectively (WHO, 2015). About 
one-eighth (12%) of the estimated cases of TB are also infected with human 
immunodeficiency virus (HIV) (WHO, 2015). In the same year, WHO estimated the 
disease prevalence as 13 million cases worldwide which was equivalent to 174 cases 
per 100 000 population. WHO also estimated that by the end of 2015, the prevalence 
rate of TB will decrease by 42% compared to 1990, which means that the target of 
halving the prevalence of TB is not likely to be met worldwide (WHO, 2015).  
 
 
2 
 
In 2014, as many as 1.1 million and 390,000 tuberculosis deaths occurred 
globally among HIV-negative and HIV- positive TB patients respectively. There are 
16 deaths per 100,000 individuals of HIV-negative TB patients. However, when 
HIV patients are included, this figure rises to 21 deaths per 100,000 individuals. 
Between 1990 and 2013, there was a decline by 47% in the global mortality rate 
among HIV-negative patients. This decline in TB mortality is due to the 
implementation of direct observation treatment short course (DOTS) strategy which 
was launched by the WHO in 1995 and considered as the most important public 
health breakthrough of the decade in term of live saved. Implementation of DOTS 
strategy ensures the proper delivery of antituberculosis drugs to the patients, 
prevents defaulting of the patients and drug‟s misuse. Consequently DOTS enhances 
the cure of the patients and prevents the development of drug resistance (WHO, 
2015).  
According to the WHO report in 2014, the incidence and the prevalence of 
tuberculosis in Malaysia was about 103; (95%CI, 83 – 124), and 135 (95% CI, 63–
232) patients per 100,000 population respectively. Mortality rate was estimated by 
the WHO as 8 (95% CI, 4.5 – 12) per 100,000 population. Overall treatment success 
rate including all case of tuberculosis was about 76% in 2013, which is relatively far 
from the global target of 85% set by the WHO (WHO, 2014).  Furthermore, the 
treatment success rate in Malaysia for HIV-positive patients and previously treated 
patients was only 51% and 30% respectively (WHO, 2014).  Although, the practice 
of DOTS strategy in Malaysia is high, ranging from 93% to 100% (Ministry of 
health, Malaysia, 2012), further efforts are required to achieve the global target of 
success rate.  
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1.2 Causes, types, and pathogenesis of tuberculosis 
The causative organism of tuberculosis remained unknown until its 
discovery in 1882, by a German scientist. By using a special technique of staining, 
Mr. Robert Koch managed to see slender rods in the tuberculous tissue, which he 
called tubercle bacilli (Herzog, 1998). This bacillus is now known as 
Mycobacterium tuberculosis, the fundamental causative organism of tuberculosis 
disease. M. tuberculosis enters the host body by inhalation of infected air. When it 
reaches the lungs; it triggers the immune system as evident by tuberculin test. The 
immune system, especially the macrophage, with an assistant from CD4 
lymphocytes, interferon gamma, and tumor necrosis factor alpha (TNFα) is able in 
80% of the cases to eradicate all the bacteria that have entered the body (Peloquin, 
2005).  In the other cases, some of the bacilli are not killed but stay surrounded by a 
defensive barrier built by the immune system. In this case, these bacilli are not 
active, and the person is neither ill nor infectious. The M. tuberculosis might remain 
years in this dormant status, which is known as latent tuberculosis (LTB) (Peloquin, 
2005; Barker, 2008; Knechel, 2009). In fact, about one-third of the world‟s 
population has LTB, but, fortunately, only 10% of them might develop an active TB 
disease in their lifetime (Barker, 2008).  
Should the immune system fail in killing or capturing the invasive 
mycobacteria, the bacilli may spread within the lung, leading to pulmonary 
tuberculosis. The bacilli may invade the lymph glands within the chest leading to 
intra-thoracic respiratory tuberculosis or further spread through the blood stream and 
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affect any other tissue leading to EPTB (Peloquin, 2005).  The active disease may 
also arise from the activation of the LTB many years after the original exposure 
(Peloquin, 2005; Barker, 2008; Knechel, 2009). Although M. tuberculosis can affect 
any tissue in the body, PTB is the most common and most infectious form of TB 
(Barker, 2008). 
1.3 Risk factors for tuberculosis  
Anyone who comes in close contact with pulmonary or laryngeal TB patients 
might get the infection. The disease is transmitted by inhaling the droplet nuclei that 
are produced when those patients cough, sneeze, talk or sing. As a result, people 
living in TB endemic area, people who have close contact with TB patients are more 
prone to get the disease (Peloquin, 2005). However, the risk of getting the infection 
and the active disease varies from one person to another according to some other 
factors, which include: 
1. The bacillary load of the index case: Sputum smear positive TB patients are much 
more infectious than smear negative patients. Furthermore, the infectivity of smear 
positive patients is increased as the concentration of the bacilli in their sputum 
increased (Espinal et al., 2000; Peloquin, 2005; Narasimhan, Wood, MacIntyre & 
Mathai, 2013). 
2. Immunity status: The risk for primary active tuberculosis and reactivation of 
latent tuberculosis is higher in people with immune compromised conditions 
(Peloquin, 2005; Narasimhan et al., 2013). Patients with HIV infection are at high 
risk to get infected by M. tuberculosis and of reactivation of LTB. Furthermore, the 
disease progression is faster and the mortality rate is higher in HIV-seropositive 
patients (Braun et al., 1991; Peloquin, 2005; Narasimhan et al., 2013). 
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3. Diabetes mellitus (DM): Presence of DM was found to be associated with about 
threefold increase in the risk of tuberculosis (Jeon & Murray, 2008; Dooley & 
Chaisson, 2009). 
4. Nutrition: Malnutrition status has also been linked to increased risk of 
tuberculosis, because of its profound effects on the immune system (Chandra, 1997; 
Cegielski & McMurray 2004; Lonnroth, Williams, Cegielski & Dye, 2010). 
5. Age: Children are at increased risk of getting the infection when they are in 
contact with infectious cases. As much as 80% of children might get the disease 
when they have prolonged close contact with smear positive patients (Marais et al., 
2004; Narasimhan et al., 2013).  
6. Tobacco smoke: The positive relationship between tobacco smoking and the 
increased incidence of TB infection and TB disease was established in a number of 
systemic reviews (Maurya, Vijayan & Shah, 2002; Pai et al., 2007; Bates et al., 
2007).  For instance, Bates et al., (2007) showed that the relative risk of TB 
infection was 1.73 higher in smokers, which indicate that the change of TB infection 
is increased by 1.73 times in smokers. Furthermore, the relative risk of TB disease 
was between 2.33 to 2.66 times higher in smokers, which indicate that the 
development of active TB disease is about 2.5 times higher in smokers.  
7. Indoor pollution: The use of biomass fuel for cooking is associated with higher 
risk of the development of TB disease (Mishra, Retherford & Smith, 1999; 
Kolappan & Subramani, 2009; Pokhrel et al., 2010). The mechanism by which 
biomass fuel could increase the risk of TB is not fully understood; however, animal 
studies have indicated that wood smoke leads to impairment of macrophage 
phagocytic function, surface adherence (Zelikoff, et al., 2002) Additionally, biomass 
combustion leads to release large particulate matter (PM) such as carbon monoxide 
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(CO), nitrogen oxide, formaldehyde, and polyaromatic hydrocarbons which can 
deposit deep into the alveoli and destroy them (Boman,  Forsberg,  & Järvholm, 
2003). 
8. Alcohol: Alcohol drinkers are at higher risk of TB disease compared with non-
alcoholic. The relative risk for TB disease was considerably higher among  people 
who consume more than 40 gram of alcohol per day or who have alcohol use 
disorder (RR = 2.94 ,95%  CI = 1.89– 4.59 ). (Lonnroth, Williams, Stadlin, 
Jaramillo & Dye, 2008). Heavy alcohol consumption deteriorates the immune 
system, specifically the production of cytokine which may explain the increased risk 
of TB disease in heavy alcohol drinkers (Szabo, 1997). 
1.4 Signs, symptoms, and diagnosis of tuberculosis 
People with LTB are often asymptomatic but show a positive reaction to the 
tuberculin test (Peloquin, 2005; Knechel, 2009). Patients with active TB disease 
typically have symptoms related to the site of the disease. The typical symptoms of 
pulmonary tuberculosis include; a chronic cough commonly with sputum, which is 
sometimes blood-stained, dyspnea, and chest pain. Systemic symptoms that might 
accompany any form of TB include fever, pallor, night sweating, loss of appetite, 
and loss of weight (Peloquin, 2005; Barker, 2008; Knechel, 2009).  
The diagnosis of TB is based on the suggestive symptoms such as a cough or 
fever for more than two weeks, and loss of weight. The diagnosis of PTB is 
confirmed by direct sputum smear for acid-fast bacilli (AFB). This test is highly 
recommended by the WHO because it is the cheapest method that can identify the 
most infectious cases. Three specimens should be collected to confirm the diagnosis 
of PTB (WHO, 2010). About 80% of patients show a positive result in the first 
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sputum specimen; 15% and 5% of patients show a positive result in the second and 
third sputum specimens respectively (Barker, 2008). The negative sputum smear 
result doesn‟t exclude PTB because more than 40% of patients with culture-positive 
PTB show a negative result with direct smear AFB (Barker, 2008).  
The chest radiograph is a sensitive but non-specific tool for diagnosis of 
pulmonary tuberculosis (Barker, 2008). Unequivocal diagnosis can only be 
accomplished by culturing the microorganism from the sputum or other biological 
specimens. Culturing the isolated bacilli is also crucial to determine the sensitivity 
of the isolated organism to the antituberculosis drugs (Barker, 2008).  
1.5 Treatment of tuberculosis 
1.5.1 Beginning the chemotherapy of tuberculosis  
The era of chemotherapy of tuberculosis was started by the discovery of 
streptomycin (SM) in 1943 by Albert Schatz and Selman Waksman. SM was the 
first antibiotic to show activity against Mycobacterium tuberculosis with an 
acceptable level of toxicity (Schatz, Bugle & Waksman, 1944). Although treatment 
with SM alone reduced the mortality of tuberculosis compared with bed rest, the 
development of resistance to SM reduced the long-term benefits of SM (Fox, Ellard, 
& Mitchison, 1999). Soon after the discovery of SM, Jorgen Lehman, a Swedish 
physician, and chemist, synthesized Para-aminosalicylic acid (PAS) in 1944. PAS 
has an advantage over SM of being administered orally. PAS was found to be 
slightly less effective than SM, but its addition to SM significantly improves the 
activity of SM, and dramatically reduces the emergence of SM-resistant mutants. It 
was the first time that the importance of combination therapy in preventing the 
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development of acquired drug resistance was recognized (Fox, Ellard, & Mitchison, 
1999).  
The great success in the history of TB treatment was made in 1952 by the 
discovery of the antituberculosis properties of isoniazid (INH) by Gerhard Domagk. 
INH alone was comparable in its efficacy to a combination of SM and PAS (Medical 
Research Council, 1952). However, INH- resistance was developed in a high 
proportion of the patients. Combination therapy with INH and SM significantly 
reduced the development of INH resistance (Medical Research Council, 1953).  
Because of the side effects of PAS, about 15% of the patients defaulted the 
standard regimen of INH, SM, and PAS (Mount & Ferebee, 1954). For this reason, 
the search for a more tolerable alternative for PAS was started. The efficacy of 
ethambutol (EMB) which was introduced in 1962 was compared with PAS. When 
used in a dose of 12.50 to 25.0 mg/ Kg, EMB was found to be as effective as PAS. 
Furthermore, substitution of PAS by EMB could also reduce the treatment period 
from 24 to 18 months (Ferebee, Doster, & Murray, 1966; Bobrowitz & Robins, 
1967; Doster, Murray, Newman, & Woolpert, 1973). 
  The second major advancement in the fight against TB was made through the 
introduction of rifampicin (rifampin, RIF) in 1963. The addition of RIF to a regimen 
consists of SM, INH, and EMB could cure more than 95% of the patients in only 
nine months (Fox, Ellard, & Mitchison, 1999; Iseman, 2002).With the availability of 
RIF and pyrazinamide (PZA), and recognition of their sterilizing activity, successful 
treatment of PTB become possible in just 6 months. This regimen is known as short-
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course chemotherapy (SCC) (Tripathy, 1982; Iseman, 2002; Zumla, Nahid, & Cole, 
2013). 
1.5.2 Current treatment of pulmonary tuberculosis patients 
For new pulmonary tuberculosis patients, WHO highly recommends the use 
of 6 months RIF-based regimen (WHO, 2010). This regimen consists of INH, RIF, 
PZA, and EMB for two months (2HRZE) as the intensive phase, followed by INH 
and RIF for four months (4HR), as the maintenance phase. Usage of RIF in the 
intensive phase only is highly discouraged because it was associated with more 
relapse and death (Menzies et al., 2009). RIF is the most powerful sterilizing agent 
in the SCC. RIF continue to exert its sterilizing effect during the whole course of 
chemotherapy by killing the semi-dormant population of M. tuberculosis which have 
spurt of active metabolism. If RIF is included in the maintenance phase, this 
population of M. tuberculosis which cannot be killed by other drugs including INH, 
will continue growing and eventually lead to disease relapse (Mitchison, 1979, 
Mitchison, 1985).   The dosages of the first-line antituberculosis agents are listed in 
Table 1.1.  
Daily administration of antituberculosis drugs during the whole course of 
treatment is the optimal way and should be applied whenever possible (WHO, 
2010).  However, when this approach is impractical, the drugs may be given daily in 
the intensive phase and intermittently during the maintenance phase, provided that, 
every dose is directly observed (WHO, 2010). The third option is to give the drugs 
three times weekly during the whole period, provided that, all the doses are directly 
observed, and the patient is HIV-negative and not living in an HIV-prevalent area 
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(WHO, 2010).  However, acquired drug resistant was significantly higher in new 
HIV-negative PTB patients who received three times weekly dosing throughout the 
therapy (Menzies et al., 2009). Furthermore, In HIV-positive patients, failure and 
relapse rate was significantly higher in patients who received intermittent intensive 
phase (Khan et al., 2010).  
EMB may be discontinued during the intensive phase if the isolated M. 
tuberculosis was susceptible to INH, RIF, and PZA (Peloquin, 2005). On the other 
hand, EMB may be added to the continuation phase, in the area where INH 
resistance is high (WHO, 2010). EMB is thought to protect RIF and prevent the 
development of multi-drug resistant (MDR) strains of M. tuberculosis (Mitchison, 
1979).  
Table 1.1 Standard doses of the first-line antituberculosis agents 
Drugs 
Route of 
administration 
Recommended dose 
Daily 3 times per week 
Dose (range) 
mg / kg body 
weight 
Maximum 
dose 
in mg. 
Dose (range) 
mg / kg body 
weight 
Maximum 
dose 
in mg. 
INH Orally 5 (4 - 6) 300 10 (8 - 12) 900 
RIF Orally 10 (8 - 12) 600 10 (8 - 12) 600 
PZA Orally 25 (20 -30) 2000 35 (30 - 40) 3000 
EMB Orally 15 (15 - 20) 1600 30 (25 - 35) 2400 
SM Intramuscular 15 (12 - 18) 1000 15 (12 - 18) 1500 
 
Adapted from WHO, Treatment of Tuberculosis Guidelines Fourth Edition (WHO, 
2010) 
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1.6 Role of individual drug in the short-course chemotherapy of tuberculosis 
1.6.1 Prevention of drug resistance 
Due to the large bacterial population present in patients with active PTB, 
naturally-occurring mutant bacilli resistant to a single drug are usually present 
(Peloquin, 2005). An addition of one or more drugs is essential to kill those bacilli 
and prevent them from growing over the sensitive ones (Mitchison, 1979; Peloquin 
2005). The efficacy of preventing the emergence of resistant strains to a specific 
drug depends on the ability of the companion drug(s) to exert a strong and 
sustainable bactericidal activity (Mitchison 1979; Mitchison, 1985). 
The relative efficacy of antituberculosis agents in this regard can be inferred 
from their prevention of treatment failure due to the development of drug-resistant 
during the treatment. RIF and SM were found to be more effective than EMB, which 
in turns was much more effective than PAS, thiacetazone (TB1) or PZA in 
preventing the emergence of INH-resistant strains (Velu et al., 1964; Mitchison, 
1979).  
INH is superior to SM in preventing the drug-resistance. Treatment failure 
occurred in 74 % of patients who received TB1 plus SM, and in 28% of patients 
who received TB1 plus INH regimen (Briggs et al., 1968). The antituberculosis 
agents can be ordered according to their activity in preventing the drug resistance as 
the follows: INH is the most effective one, followed by RIF and SM. EMB is less 
effective, but still much better than PZA (Mitchison, 1979; Mitchison 1985) 
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1.6.2 Sterilizing activity 
The sterilizing activity is defined as the speed with which the last viable 
bacilli are eradicated (Mitchison, 1985). As a result, incorporation of drugs with 
high sterilizing activity in the treatment regimen will lead to a fast elimination of the 
bacilli and shortening of the treatment period (Mitchison 1979; Mitchison, 1985).  In 
clinical studies, the sterilizing activity of a given regimen is measured by the rate of 
sputum culture conversion to negative after two months of therapy, or the rate of 
relapse after the drugs have been discontinued (Mitchison, 1979; Tripathy, 1982; 
Mitchison, 1985). In clinical trials, the addition of PZA or RIF to regimen consisted 
of SM and INH, significantly increased the 2-months culture conversion rate, and 
decreased the relapse rate, whereas the addition of TB1 did not do so. Therefore, 
both RIF and PZA have high sterilizing effects but TB1 does not (Fox, Ellard, 
&Mitchison 1999). The addition of SM to a regimen of INH and RIF slightly but not 
significantly reduced the relapse rate and increased the 2-months culture conversion 
rate. Thus, SM appears to have very little sterilizing activity (Mitchison, 1979; 
Mitchison, 1985; Mitchison, 2000). While both RIF and PZA have the highest 
sterilizing activity, it was clear that RIF exerts its activity during the whole course of 
treatment while the activity of PZA diminished after the first two months (Fox, 
Ellard, &Mitchison 1999). 
  Replacing PZA by EMB significantly increased the relapse rate and 
decreased the 2-months culture conversion rate, which indicated the poor sterilizing 
activity of EMB (Fox, Ellard, &Mitchison 1999). In conclusion, RIF and PZA are 
the main sterilizing drugs; SM has a moderate sterilizing activity while EMB has no 
sterilizing activity (Mitchison, 1979, Mitchison, 1985, Mitchison, 2000) 
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1.6.3 Bactericidal activity  
The inherent bactericidal activity of any antituberculosis drug or regimen is 
best estimated by the early bactericidal activity during the first two days of treatment 
(EBA0-2) (Mitchison, 1979). The early bactericidal activity was measured as the fall 
in the counts of colony forming unit (CFU) of patients' sputum at different interval 
of the treatment. The first study of this kind was conducted in Nairobi by Dr. Amina 
Jindani and colleagues (Jindani, Aber, Edwards, & Mitchison, 1980; Jindani, Dore, 
& Mitchison, 2003). Following this study, a number of similar studies were 
conducted in different countries; these studies have been reviewed by Donald and 
Diacon (Donald & Diacon, 2008). The results of all EBA studies can be summarized 
in the following finding; 1) Mycobacterium tuberculosis is killed much more rapidly 
during the first two days of the treatment; 2) bactericidal activity of INH is much 
higher than that of any other single agent; 3) the EBA activity of any agent is 
increased considerably by addition of INH; 4) the high bactericidal activity of INH 
is dramatically reduced after the first two days; 5) RIF has much less bactericidal 
activity than INH in the initial two days, but it maintains its activity during the latter 
period; 6) the high sterilizing activity of RIF and PZA  cannot be explained on the 
basis of their bactericidal activity since both drugs have modest bactericidal activity  
(Mitchison, 1979; Mitchison, 2000; Donald, & Diacon, 2008).  
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1.7 Basic pharmacology of INH, RIF, and PZA 
1.7.1 Basic pharmacology of INH 
After oral administration, INH is rapidly and completely absorbed and 
reaches its Cmax within 1- 2 hours when taken on an empty stomach (Douglas, & 
McLeord, 1999; Peloquin 2002; Budha, Lee, & Meibohm, 2008). Food, especially 
high-fat meals decrease and delay its absorption, leading to a reduction of its Cmax 
almost to the half, and doubling of its Tmax (Lin, Lin, Chan, & Lu, 2010). It is 
metabolized in the liver by acetylation and dehydrazination. The acetylation 
pathway is mediated by N-acetyl transferase 2 (NAT2) (Budha, Lee, & Meibohm, 
2008). The patients are either slow acetylator or rapid acetylator. The serum half-life 
(t1/2) of INH is about 1.5 hours in rapid acetylator and about 4 hours in slow 
acetylator.  Most Asians and about half of Caucasian and Blacks are rapid acetylator 
(Douglas, & McLeord, 1999; Budha, Lee, & Meibohm, 2008).  
INH enters tubercle bacilli by passive diffusion and gets activated by M. 
tuberculosis catalase-peroxidase enzyme (KatG), which is encoded by the katG gene 
(Shi, Itagaki, & Sugawara, 2007; Budha, Lee, & Meibohm, 2008). This activation 
leads to a production of a wide variety of compounds includes; isonicotinic acyl-
NADH, an enoyl carrier protein reductase “InhA” inhibitor, reactive oxygen species, 
hydroxyl radicals and reactive organic species. These reactive species and radicals 
affect the M. tuberculosis at multiple cellular targets and eventually lead to bacterial 
cell death (Lei, Wei, & Tu, 2000; Shi, Itagaki, & Sugawara, 2007).  Inhibition of 
InhA enzyme that catalyzes the final step in elongation of mycolic acid is the most 
important mechanism by which INH kills the M. tuberculosis (Vilchèze et al., 
2000).  
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Adverse effects of INH are dose-related. At the typical doses of 3-5 mg/kg, 1 
to 5 % of patients experience some of its adverse effects. At a dose of 10 mg/kg, the 
adverse effects may occur in 15 % of the patients (Goldman & Braman, 1972). 
Peripheral neuropathy is the commonest toxic effect of INH. It occurs as a result of 
increased pyridoxine excretion, leading to pyridoxine deficiency. It is especially 
prevalent in alcoholism, malnutrition, and slow acetylator (David & Leahy, 1959; 
Goldman & Braman, 1972). INH-induced peripheral neuropathy is preventable and 
reversible by administration of pyridoxine (Goldman & Braman, 1972). Central 
nerves system adverse effects include; headache, irritability, restlessness, lethargy, 
drowsiness, seizure, and encephalopathy. Depression and other psychological effects 
such as unbalanced state of mind, impaired memory were reported during INH 
therapy, especially in alcoholism, and in patients with a history of mental illness 
(Goldman & Braman, 1972; Cheung, Lo, Lo, Ip, & Cheng, 1993).  
Clinical hepatitis induced by INH is a very severe side effect that occurs in 
1% of the patients and requires immediate drug discontinuation. It is manifested by 
loss of appetite, nausea, vomiting, jaundice, and right upper quadrant pain. In most 
cases, INH-induced hepatitis occurs three months after the initiation of drug therapy, 
but it might occur after one week in some patients (Goldman & Braman, 1972; 
Tostmann et al., 2008). The risk of INH-induced hepatitis is higher in alcoholics, 
during pregnancy, and with advanced age (Thompson et al., 1995).  
1.7.2 Basic pharmacology of RIF  
RIF is well absorbed after oral administration, and reaches its maximum 
concentration after 2 - 4 hours (Douglas, & McLeord, 1999; Peloquin 2002; Budha, 
Lee, & Meibohm, 2008). The food decreases and delays its absorption, leading to a 
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significant reduction in its Cmax and considerable increases in its Tmax (Lin, Lin, 
Chan, & Lu, 2010).  RIF is metabolized in the liver to 25-desacytyl RIF, which 
retains most of the RIF activity. Owing to its potent enzyme induction property, RIF 
induces its own metabolism (auto-induction). The serum half-life of RIF is reduced 
by about 40% in the first two weeks of its administration as a result of its auto-
induction property (Benedetti, & Dostert, 1994).  
RIF acts by binding to and inhibiting DNA-dependent RNA polymerase, the 
binding of RIF occurs at the β subunit of this enzyme leading to blocking of the 
elongation process of the growing RNA. Most of the resistance to RIF occurs as a 
result of a mutation in this β subunit gene (rpo B) (Hartmann, Honikel, Knusel, & 
Nuesch, 1967; Shi, Itagaki, & Sugawara, 2007; Budha, Lee, & Meibohm, 2008).  
Hepatotoxicity is the most serious adverse effect of RIF. When RIF was used 
alone as a preventive therapy for patients who cannot tolerate INH, the incidence of 
hepatotoxicity was found to be in the range of 1 - 2 % (Villarino et al., 1997; 
Tostmann et al., 2008).  When RIF was given with non-hepatotoxic drugs (EMB or 
SM) the incidence of hepatotoxicity was about 1.1% (Steele, Burk, & DesPrez, 
1991). RIF significantly increases the hepatotoxicity of INH, probably due to 
increasing INH metabolism and the production of its hepatotoxic metabolites 
(Steele, Burk, & DesPrez, 1991; Tostmann et al., 2008).The mechanism by which 
RIF causes hepatotoxic effect is not clear, nor predictable. However, it seems to 
involve hypersensitivity reaction and appears to be dose dependent, and more 
frequent with large intermediate dosage (Martinez, Collazos, & Mayo, 1999; 
Saukkonen et al., 2006; Tostmann et al., 2008). RIF may cause a flu-like syndrome, 
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especially if given less frequently than twice weekly (Addington, 1979; Chan-
Tompkins, 1995).  
1.7.3 Basic pharmacology of PZA  
PZA is readily absorbed after oral administration, reaching its maximum 
concentration after 1 to 2 hours (Peloquin 2002; Budha, Lee, & Meibohm, 2008). 
The food and antacid slightly reduce the Cmax of PZA (Lin, Lin, Chan, & Lu, 2010).  
PZA is hydrolyzed by a microsomal deaminase to the active metabolite, the 
pyrazinoic acid (POA). Pyrazinoic acid is then hydroxylated by xanthine oxidase to 
5-hydroxypyrazoinoic acid. The serum half-life of PZA is about nine hours (Budha, 
Lee, & Meibohm, 2008). 
Despite its importance in the treatment of tuberculosis, the mechanism of 
action of PZA is still not fully understood. PZA is a prodrug, it is converted to its 
active form pyrazinoic acid (POA) by bacterial nicotinamidase/pyrazinamidase 
(PZase) which is encoded by the gene pncA (Zhang, & Mitchison, 2003). POA 
disrupts the membrane energetics and inhibits membrane transport function in 
Mycobacterium tuberculosis (Zhang, Wade, Scorpio, Zhang, & Sun, 2003). 
Resistance to PZA occurs due to inactivation of (PZase) enzyme as a result of a 
mutation in pncA gene (Zhang, Wade, Scorpio, Zhang, & Sun, 2003; Zhang, & 
Mitchison, 2003). 
The activity of PZA depends on the pH of the medium. It shows no activity 
under normal culture condition, but shows high activity in acidic condition. The 
activity of PZA in acidic medium makes it ideal for killing the bacilli that live in 
acidic phagosomes inside the infected macrophages. The activity of PZA against this 
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bacterial population increases as the growth rate of this organism decline 
(Mitchison, 1979). 
Hyperuricemia and non-gouty polyarthralgia are the most common side 
effects of PZA. Half of the patients may experience an asymptomatic elevation of 
serum uric acid, due to the inhibition of urinary excretion of uric acid (Zierski, & 
Bek, 1980; Steele, & Des Prez, 1988). The incidence of symptomatic arthralgia 
ranges from 1% to 7% depends on the dose of PZA and frequency of its 
administration (Jenner et al., 1981). Interestingly, treatment with RIF has been 
shown to decrease the incidence of PZA-induced arthralgia, probably due to the 
enhancement of uric acid excretion and decrease of its deposition in the joints 
(Sarma et al., 1983).  Hepatotoxicity is the major serious adverse effect of PZA. 
With the currently recommended dose of 20 - 30 mg/Kg, the incidence of PZA-
induced hepatotoxicity is about 2%, which is similar to INH or RIF-induced 
hepatitis (Yee et al., 2003).  
1.8 Problem statements 
First-line antituberculosis agents (INH, RIF, and PZA) are administered in 
doses based on patients‟ body weight, which is the only factor that has been 
considered in calculating the dose (WHO, 2010). In most cases, the recommended 
weight-adjusted doses of these agents are appropriate and lead to successful 
treatment. However, in some cases, the treatment failure may be due to 
inappropriate doses, and therefore individualizing the drug doses for those patients 
could improve their treatments outcomes (Yew, 2001; Peloquin, 2002). 
Individualizing the drugs‟ doses can be guided by the use of therapeutic drug 
monitoring (TDM).  TDM can be simply defined, as measuring the concentration of 
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a drug in the biological fluid, and adjustment of its dose accordingly.  The purpose 
of TDM is to achieve the desirable drug level that leads to maximum efficacy and 
minimum toxicity (Kang, & Lee, 2009).  
For any drug to be a candidate for TDM, the following criteria should be 
met: 1) Good correlation between the drug exposure and its clinical efficacy or 
toxicity or both must be established. 2) A definite therapeutic range has been set. 3) 
Significant pharmacokinetic variability is expected among the patients (Kang, & 
Lee, 2009).  
In the case of INH, RIF, and PZA some of these criteria are not yet met. This 
issue will be discussed in more details in the next chapter. In summary, the 
following reasons are precluding the routine use of TDM to guide the dosing of 
these antituberculosis agents: 
1. Further evidence is required for better judgment of the relationship between drug 
exposure and clinical efficacy as it remains contrary. 
2. A definite therapeutic range has not been established for INH, RIF, and PZA.  
The Cmax is the target for TDM because their trough concentration is usually below 
the detection limit and of no clinical value (Peloquin, 2002). However, there are two 
major problems with the utility of the Cmax of these agents. Firstly the exact ranges 
of the Cmax of these agents are not well-defined. Secondly, the time to reach the Cmax 
(Tmax) varies from drug to another and from patient to patient regarding the same 
drug.  
3. There is some contradictory about the factors that determine the Cmax of INH, 
RIF, and PZA, such as the effect of patient‟s body weight, the patient‟s age, the 
20 
 
patient‟s gender, and the presences of other disease. This issue will be discussed in 
details in the next chapter.  
1.9 Rational of the study 
INH, RIF, and PZA   are essential drugs in the treatment of tuberculosis. 
These agents are administered in fixed-doses based on the patient‟s body weight. 
Although WHO guideline for management of tuberculosis (WHO, 2010) stated a 
maximum dose of each drug that should not be exceeded, some authors don‟t agree 
with the use of term “maximum dose” and believe that, the maximum dose of a 
particular drug for a particular patient is the highest dose of that drug that the patient 
can tolerate, with an acceptable benefit/risk ratio (Peloquin, 2002). 
This study is designed to test the concentration-response relationship of INH, 
RIF, and PZA. The outcomes being explored are the treatment success rate and 
development of adverse drug reaction. The independent variables of interest are the 
plasma concentration of INH, RIF, and PZA. If the study could establish a 
significant association between the concentration of any one of these drugs and 
patients‟ response or development of drug side effects, it would be rational to use 
the therapeutic drug monitoring (TDM) to guide antituberculosis therapy. The 
second main objective of this study is to find out the patients‟ demographic and 
clinical factors that may affect the plasma concentration of these drugs. Identifying 
those patients will allow the physician to pay more care to them which will lead to 
more successful management. 
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1.10 Aim of the study 
 To obtain a baseline pharmacokinetic data concerning the blood concentration 
of INH, RIF, and PZA in Malaysian tuberculosis patients and to assess the influence 
of these pharmacokinetics data on the treatment of pulmonary tuberculosis patients    
1.10.1 Specific objectives of the study 
1. To develop and validate high-performance liquid chromatography methods for 
determination of INH, PZA and RIF in human plasma. 
2. To measure the plasma concentrations of INH, RIF, and PZA in a cohort of 
Malaysian tuberculosis patients.  
3. To assess the effect of the pharmacokinetics of INH, RIF and PZA on the 
treatment outcomes of PTB patients and the occurrence of drug adverse effects. 
4. To find out the clinical and social factors with significant effects on the plasma 
concentration of INH, RIF, and PZA. 
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CHAPTER 2 
LITERATURE REVIEW 
 
2.0. Pharmacokinetics and pharmacodynamics of INH, RIF, and PZA 
In general, antibacterial agents are either bactericidal or bacteriostatic. INH, 
RIF, and PZA are all bactericidal drugs (Nuermberger & Grosset, 2004). The 
bactericidal drugs can be divided into two categories based on the pattern of their 
bactericidal activity. The first category is the concentration-dependent bactericidal 
agents, for which the rate of killing is increased by increasing the concentration of 
the drug at the site of infection. For these antibacterial agents, the rate of bacterial 
killing is best correlated with the Cmax/MIC or the AUC/MIC ratio (Craig, 1998). To 
achieve the highest bactericidal activity of these antibiotics, they should be given at 
the largest safe dose that yields the highest possible concentration of the drug at the 
site of infection (Craig, 1998; Nuermberger & Grosset, 2004).  
Animal studies and in vitro studies indicate that INH, RIF, and PZA are 
bactericidal drugs with concentration-dependent activity. In a murine model of 
aerosol infection, Jayaram et al., (2003) demonstrated that the bactericidal activity 
of RIF is best correlated with its AUC/MIC ratio (r
2
 = 0.95), followed by its 
Cmax/MIC ratio (r
2
 = 0.86). In another experiment on the same model, Jayaram et al., 
(2004) found that INH is exhibiting a concentration-dependent bactericidal effect on 
extracellular M. tuberculosis. This bactericidal activity was related to AUC0-24h / 
MIC ratio and was not related to the duration of exposure.  
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Gumbo et al., (2009) showed that the sterilizing activity of PZA was related 
to its AUC0-24h/ MIC ratio and 90% of the maximal effect was achieved when this 
ratio was equal to 209. In contrast, the ability of PZA to suppress the emergence of 
bacterial resistance was best correlated with the duration of time in which the 
concentration of PZA remains above its MIC (TMIC). This observation indicates that 
both the dose size and administration schedule are important for PZA to exhibit its 
sterilizing and resistance-suppression activities.  
2.1 Literature search  
The following databases; PubMed, EMBASE, Cochrane Library, were 
searched for the studies that were published in English and was investigating any of 
the following issues; 1) the pattern of INH, RIF or PZA concentration in the blood, 
2) factors affecting the concentration of INH, RIF, or PZA in TB patients or healthy 
volunteers, 3) the relationship between the concentration and activity of INH, RIF, 
and PZA, 4) the relationship between the concentration of INH, RIF or PZA and the 
development of adverse drug reaction (ADR). The keyword used for the search were 
„concentration‟ or „level‟ or „peak‟ AND „antituberculosis‟ or „antimycobacterial‟ or 
isoniazid „INH‟ or „rifampicin‟ (RIF) or „pyrazinamide‟ (PZA) AND „patients 
response‟ or patients outcome‟ or development/incidence of adverse drug 
reaction/side effects or AND „factor affecting‟ or „determinants‟. Only human 
studies that include adult tuberculosis patients or adult healthy volunteer were 
included.  Any study design such as randomized clinical trial, prospective study, 
retrospective cohort study, case-control study, was accepted. Review articles and 
meta-analysis studies were also considered for the review purpose.  
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The studies identified and accepted for this literature review can be divided 
into three groups 
1. Explanatory studies which measure the pharmacokinetic parameters of INH, RIF 
or PZA and correlate them with the treatment outcomes or development of ADR. 
The subjects of such study must be adults with PTB with or without other forms of 
EPTB.  
2. Explanatory studies which measure the pharmacokinetic parameters of 
antituberculosis agents and address the factors that affect those pharmacokinetic 
parameters. The subject of these studies may include adult healthy volunteers, or 
adult TB patients with or without other comorbidities, or both.   
3. Observatory studies that measure the pharmacokinetics of INH, RIF, and PZA 
without explaining the variability in those pharmacokinetic parameters or correlating 
the pharmacokinetic parameters with the treatment success or development of 
ADRs. 
2.1.1 The relationship between the pharmacokinetics of INH, RIF, and PZA 
and the treatment outcomes of PTB patients 
Gangadharam et al., (1961) measured the serum concentration of INH in 
sub-group of patients who participated in clinical trials in India (Tuberculosis 
Chemotherapy Centre, 1960). The patients were divided into four groups to receive 
one of the following regimens; 400 mg of INH once a day (HI-1), 200 mg of INH 
twice a day (HI-2), 200 mg of INH once a day (H), or 100 mg of INH plus PAS 5 
mg twice a day (HP). The serum concentration of INH was higher in patients who 
received 400 mg of INH in a single dose than the patients who received 200 mg of 
INH twice daily. For slow-acetylator, the Cmax of INH was 6.6 mg/L and 2.6 mg/L in 
